Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: the patienttherapyrandomizationradiationactive
  Phrases that lowered it: days beforescreeningvisitinfectedresistance
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 70 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 13 (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 NCT02707861 · started 2016 · scored riskier than 20% of active trials completed
• Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV NCT02475629 · started 2015 · scored riskier than 17% of active trials completed
• Investigator-Sponsored Protocol - Continued Use of Ibalizumab NCT01056393 · started 2009 · scored riskier than 25% of active trials completed
• Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers NCT01292174 · started 2011 · scored riskier than 2% of active trials completed
• A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 NCT06032546 · started 2023 · scored riskier than 22% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.